Park Square Financial Group’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-600
Closed -$52.8K – 773
2025
Q2
$52.8K Hold
600
– – 0.04% 290
2025
Q1
$54.7K Buy
600
+100
+20% +$9.01K 0.04% 252
2024
Q4
$43.1K Buy
+500
New +$45.2K 0.03% 300

Other funds holding PPH

Park Square Financial Group's PPH Position: Q3 2025 in Review

Park Square Financial Group sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2025, closing a stake of 600 shares — an estimated $52.8K sold.

Park Square Financial Group first reported a position in PPH in Q4 2024 and held it in 3 quarters. The position peaked at $54.7K in Q1 2025. 127 funds tracked by Wall St. Rank hold PPH as of Q3 2025.

  • Park Square Financial Group reported no remaining VanEck Pharmaceutical ETF position as of Q3 2025 after selling out during the quarter.
  • Park Square Financial Group sold 600 VanEck Pharmaceutical ETF shares in Q3 2025, an estimated $52.8K.
  • Park Square Financial Group first reported a position in VanEck Pharmaceutical ETF in Q4 2024 and held it in 3 quarters.
  • Park Square Financial Group's VanEck Pharmaceutical ETF position peaked at $54.7K in Q1 2025.
  • 127 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2025.

Based on Park Square Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.